Abstract:Background Cholestatic liver injury is an important clinical problem with a limited understanding of disease pathologies. Modulation of the enterohepatic circulation of bile acids (BAs) may protect against BA‐mediated cholestatic liver injury. Berberine (BBR), a bioactive isoquinoline alkaloid found in a variety of herbs, has been used to treat many diseases, including liver diseases, over hundreds of years. Our previous studies have shown that BBR inhibits high fat‐diet‐induced steatosis and inflammation in rodent models of nonalcoholic fatty liver diseases. However, it remains unknown if BBR has any effect on cholestatic liver injury. The aim of this study is to examine the therapeutic effects and potential mechanisms of berberine on cholestatic liver disease in Mdr2 −/− mice, the best‐characterized mouse model of primary sclerosing cholangitis (PSC). Methods Mdr2 −/− mice with FVB background (100 days old, both male and female) were randomly divided into the control group and BBR group. Mice were treated with BBR (50 mg/kg) or vehicle (0.5% carmellose sodium solution) by intragastric administration once‐daily for eight weeks. Mice were kept in a temperature‐controlled room with 12/12‐hour light/dark cycles and fed ad libitum normal chow diet. At the end of the treatment, the mice were sacrificed. Blood was collected for measuring serum lipids and liver functional enzymes using the Alfa Wassermann Vet ACE Axcel® System. Liver tissues were processed for H&E and Masson’s trichrome staining, immunohistochemistry (IHC), and isolation of total RNA. The mRNA levels of the key genes involved in bile duct proliferation, inflammation, fibrotic injury, and bile acid metabolism were measured by real‐time RT PCR. Results BBR treatment significantly improved cholestatic liver injury as indicated by significant reduction of serum levels of ALT, AST, ALP, and BAs, as well as liver to body weight ratios. H&E and Masson's trichrome staining showed a significant reduction of liver fibrosis by BBR treatment. IHC staining of CK‐19 further showered that BBR treatment markedly reduced biliary proliferation and ductular reaction. In addition, BBR treatment reduced hepatic macrophage infiltration. Real‐time PCR results further showed that BBR treatment significantly reduced the mRNA levels of MCP‐1, IL‐1β, α‐SMA, CK‐19 and increased mRNA levels of FXR and SHP in the liver. Conclusion BBR significantly reduced cholestatic liver injury and has the potential to be used for the treatment of PSC and other cholestatic liver diseases. Support or Funding Information This work was supported by VA Merit Award I01BX004033 and 1I01BX001390, VA Career Scientist Award IK6BX004477 and National Institutes of Health Grant R01 DK104893 and R01DK‐057543

Berberine alleviates cholesterol and bile acid metabolism disorders induced by high cholesterol diet in mice

The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression

Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver

Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients

Dose-response effect of berberine on bile acid profile and gut microbiota in mice

Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome

Effect of Berberine on Atherosclerosis and Gut Microbiota Modulation and Their Correlation in High-Fat Diet-Fed ApoE−/− Mice

Berberine Improves High-Fat Diet Induced Atherosclerosis and Hepatic Steatosis in Apoe-/-Mice by Down-Regulating PCSK9 via ERK1/2 Pathway

Effect of Berberine on Promoting the Excretion of Cholesterol in High-Fat Diet-Induced Hyperlipidemic Hamsters

Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids

Berberine alleviates high-energy and low-protein diet-induced fatty liver hemorrhagic syndrome in laying hens: insights from microbiome and metabolomics

Berberine improves DSS-induced colitis in mice by modulating the fecal-bacteria-related bile acid metabolism

Berberine attenuates cholestatic liver and bile duct injury in Mdr2<SUP>-/-</SUP> mice by maintaining bile acid homeostasis

Berberine attenuates atherosclerotic lesions and hepatic steatosis in ApoE-/- mice by down-regulating PCSK9 via ERK1/2 pathway

Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway

Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota

Berberine inhibits high fat diet-associated colorectal cancer through modulation of the gut microbiota-mediated lysophosphatidylcholine

Berberine Improves Vascular Dysfunction by Inhibiting Trimethylamine-N-oxide via Regulating the Gut Microbiota in Angiotensin II-Induced Hypertensive Mice

Berberine Attenuates Hyperuricemia by Regulating Urate Transporters and Gut Microbiota

Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells

Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds